Relevance of the Weber effect in contemporary pharmacovigilance of oncology drugs

References

• PalleriaCLeporiniCChimirriSLimitations and obstacles of the spontaneous adverse drugs reactions reporting: two “challenging” case reportsJ Pharmacol Pharmacother20134Suppl 1S66S7224347986
   PubMedGoogle Scholar
• NauckMAFriedrichNDo GLP-1–based therapies increase cancer risk?Diabetes Care201336Suppl 2S245S25223882053
   PubMed Web of Science ®Google Scholar
• WeberJCPEpidemiology of adverse reactions to nonsteroidal anti-inflammatory drugsRainsfordKDVeloGDSide-effects of Anti-inflammatory Drugs, Advances in Inflammation ResearchNew YorkRaven Press198417
   Google Scholar
• HartnellNRWilsonJPReplication of the Weber effect using postmarketing adverse event reports voluntarily submitted to the United States Food and Drug AdministrationPharmacotherapy200424674374915222664
   PubMed Web of Science ®Google Scholar
• HartnellNRWilsonJPPatelNCCrismonMLAdverse event reporting with selective serotonin-reuptake inhibitorsAnn Pharmacother200337101387139114519041
   PubMed Web of Science ®Google Scholar
• McAdamsMAGovernaleLASwartzLHammadTADal PanGJIdentifying patterns of adverse event reporting for four members of the angiotensin II receptor blockers class of drugs: revisiting the Weber effectPharmacoepidemiol Drug Saf200817988288918636418
   PubMed Web of Science ®Google Scholar
• United States Food and Drug Administration (USFDA)FAERS Reporting by Healthcare Providers and Consumers by Year Available from: http://www.fda.gov/Drugs/GuidanceComplianceRegulatoryInformation/Surveillance/AdverseDrugEffects/ucm070456.htmAccessed March 2017
   Google Scholar
• SakaedaTTamonAKadoyamaKOkunoYData mining of the public version of the FDA Adverse Event Reporting SystemInt J Med Sci201310779680323794943
   PubMed Web of Science ®Google Scholar
• United States Food and Drug Administration (USFDA)FDA Adverse Event Reporting System (FAERS) Statistics Available from: https://www.fda.gov/Drugs/GuidanceComplianceRegulatoryInformation/Surveillance/AdverseDrugEffects/ucm070434.htmAccessed June 12, 2016
   Google Scholar
• ChhabraPChenXWeissSRAdverse event reporting patterns of newly approved drugs in the USA in 2006: an analysis of FDA Adverse Event Reporting System dataDrug Saf2013361117112324078293
   PubMed Web of Science ®Google Scholar
• HoffmanKBDimbilMErdmanCBTatonettiNPOverstreetBMThe Weber effect and the United States Food and Drug Administration’s Adverse Event Reporting System (FAERS): analysis of sixty-two drugs approved from 2006 to 2010Drug Saf20143728329424643967
   PubMed Web of Science ®Google Scholar
• United States Food and Drug Administration (USFDA)What is Data Mining?USFDA Available from: http://www.fda.gov/ohrms/dockets/ac/06/briefing/2006-4266b1-02-06-FDA-appendic-f.pdfAccessed March 15, 2017
   Google Scholar
• European Medicines AgencyEMA Guidance Document. Guideline on the Use of Statistical Signal Detection Methods in the Eudravigilance Data Analysis SystemLondonEuropean Medicines Agency2008 Ref. EMEA/106464/2006 rev.1. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/Regulatory_and_procedural_guideline/2009/11/WC500011434.pdfAccessed March 15, 2017
   Google Scholar
• HarpazRDuMouchelWShahNHMadiganDRyanPFriedmanCNovel data mining methodologies for adverse drug event discovery and analysisClin Pharmacol Ther20129161010102122549283
   PubMed Web of Science ®Google Scholar
• ChopraDRehanHSSharmaVMishraRChemotherapy-induced adverse drug reactions in oncology patients: a prospective observational surveyIndian J Med Paediatr Oncol2016371424627051157
   PubMed Web of Science ®Google Scholar
• BaldoPDe PaoliPPharmacovigilance in oncology: evaluation of current practice and future perspectivesJ Eval Clin Pract201420555956924909067
   PubMed Web of Science ®Google Scholar
• OshimaYTsukamotoHTojoAAssociation of hepatitis B with antirheumatic drugs: a case-control studyMod Rheumatol201323469470422802011
   PubMed Web of Science ®Google Scholar
• WillemenMJMantel-TeeuwisseAKStrausSMMeyboomRHEgbertsTCLeufkensHGUse of dipeptidyl peptidase-4 inhibitors and the reporting of infections: a disproportionality analysis in the World Health Organization VigiBaseDiabetes Care201134236937421270195
   PubMed Web of Science ®Google Scholar
• DavenportMSDillmanJRCohanRHEffect of abrupt substitution of gadobenate dimeglumine for gadopentetate dimeglumine on rate of allergic-like reactionsRadiology2013266377378223238152
   PubMed Web of Science ®Google Scholar
• de GraafLFabiusMADiemontWLvan PuijenbroekEPThe Weber-curve pitfall: effects of a forced introduction on reporting rates and reported adverse reaction profilesPharm World Sci200325626026314689813
   PubMedGoogle Scholar
• MannucciPMAnticoagulanti orali diretti: una sfida per la farmacovigilanza [Direct oral anticoagulants: a new challenge for pharmacovigilance]Focus Farmacovigilanza20148131 Italian
   Google Scholar
• FDA Advisory CommitteeSanofi-aventis USPresentation on Ketek® (telithromycin)2006 Available from: https://www.fda.gov/ohrms/dockets/ac/06/slides/2006-4266s1-02-06-Ketek-Rullo.pdfAccessed March 15, 2017
   Google Scholar
• SouthworthMRReichmanMEUngerEFDabigatran and postmarketing reports of bleedingN Engl J Med2013368141272127423484796
   PubMed Web of Science ®Google Scholar
• MotolaDBiagiCLeoneRTiclopidine safety profile: a case/non-case study on the basis of the spontaneous ADRs reporting in ItalyCurr Drug Saf2012729910522873494
   PubMedGoogle Scholar
• MatsudaSAokiKKawamataTBias in spontaneous reporting of adverse drug reactions in JapanPLoS One2015105e012641325933226
   PubMed Web of Science ®Google Scholar
• United States Food and Drug Administration (USFDA)New Molecular Entity (NME) Drug and New Biologic ApprovalsUSFDA Available from: https://www.fda.gov/Drugs/DevelopmentApprovalProcess/HowDrugsareDevelopedandApproved/DrugandBiologicApprovalReports/NDAandBLAApprovalReports/ucm373420.htmAccessed March 15, 2017
   Google Scholar
• CenterWatch2004 FDA Approved DrugsCenterWatch Available from: https://www.centerwatch.com/drug-information/fda-approved-drugs/year/2004Accessed March 15, 2017
   Google Scholar
• United States Food and Drug Administration (USFDA)Drugs@FDA: FDA Approved Drug ProductsUSFDA Available from: http://www.accessdata.fda.gov/scripts/cder/daf/Accessed March 15, 2017
   Google Scholar
• Patented Medicine Prices Review Board (PMPRB)Patented Medicine Prices Review BoardPMPRB Available from: http://www.pmprb-cepmb.gc.ca/homeAccessed June 10, 2017
   Google Scholar
• United States Food and Drug Administration (USFDA)Open FDAUSFDA Available from: https://open.fda.gov/drug/event/Accessed February 22, 2017
   Google Scholar
• KasliwalRSpontaneous reporting in pharmacovigilance: strengths, weaknesses and recent methods of analysisThe Journal of Clinical and Preventive Cardiology201212023 Berkshire, UK: JCPC; 2015. Available from: http://www.jcpcarchives.org/full/spontaneous-reporting-in-pharmacovigilance--strengths-49.phpAccessed March 15, 2017
   Google Scholar
• PoluzziERaschiEPiccinniCDe PontiFData Mining Techniques in Pharmacovigilance: Analysis of the Publicly Accessible FDA Adverse Event Reporting System (AERS) Chapter 12. Available from: http://dx.doi.org/10.5772/50095Accessed March 15, 2017
   Google Scholar
• FangHSuZWangYExploring the FDA adverse event reporting system to generate hypotheses for monitoring of disease characteristicsClin Pharmacol Ther201495549649824448476
   PubMed Web of Science ®Google Scholar
• Weiss-SmithSDeshpandeGChungSGogolakVThe FDA drug safety surveillance program: adverse event reporting trendsArch Intern Med2011171659159321444854
   PubMedGoogle Scholar
• WallensteinEJFifeDTemporal patterns of NSAID spontaneous adverse event reports: the Weber effect revisitedDrug Saf200124323323711347725
   PubMed Web of Science ®Google Scholar
• United States Food and Drug Administration (USFDA)Approved Risk Evaluation and Mitigation Strategies (REMS) Available from: http://www.accessdata.fda.gov/scripts/cder/rems/index.cfmAccessed March 15, 2017
   Google Scholar
• United States Food and Drug Administration (USFDA)Milestones in Food and Drug Law History Available from: http://www.fda.gov/aboutfda/whatwedo/history/milestones/ucm081229.htmAccessed March 15, 2017
   Google Scholar
• HartAHenwoodFWyattSThe role of the Internet in patient-practitioner relationships: findings from a qualitative research studyJ Med Internet Res200463e3615471762
   PubMed Web of Science ®Google Scholar
• IlicDThe role of the internet on patient knowledge management, education, and decision-makingTelemed J E Health201016666466920575610
   PubMed Web of Science ®Google Scholar